Study of Some Immune Changes That Related to Leishmania (CL) Infection

Maha Mahmoud  Shaker

doi:10.21070/pels.v6i0.2063

(1) * Maha Mahmoud Shaker Environmental health department, college of environment science, Al-Qasim Green University, Babylon 51013,Iraq
Iraq
(*) Corresponding Author

DOI: https://doi.org/10.21070/pels.v6i0.2063

Abstract

Cutaneous leishmaniasis is an infection of the skin. The symptoms graduated causes bumps that after that turn into ulcers (large) in the future. Healing may take a long time. Symptoms begin within weeks or may be months after bite of sand fly.This study was conducted in the city of Hilla. This study included 90 patients who were selected from visitors to private clinics. These study participants were then divided into two groups of similar ages. The first group included 60 people with cutaneous leishmaniasis who were diagnosed by a doctor, in addition to a second group that included 30 people who were not infected with any disease as a control group. Cytokine concentrations were also measured using... ELISA technique, then statistical testing was performed. Results: showed high concentration of the cytokines that were under study interleukin 17 and interleukin 33 in the patient group compared to the group of control. Conclusions and recommendations: The increase in the level of cytokines in the patient group may indicate the role that these cytokines play in the regression of the disease

Highlights:

Cutaneous Leishmaniasis: Skin infection causing bumps, ulcers, slow healing.
Study Groups: 60 patients, 30 controls, cytokines measured via ELISA.
Findings: Elevated IL-17, IL-33 indicate cytokines' role in disease regression.

Keywords: Cutaneous leishmaniasis, cytokines, interleukin-17, interleukin-33, ELISA

Downloads

Download data is not yet available.

References

. M. S. Gruel, B. Tekin, and S. Uzun, "Cutaneous Leishmaniasis: A Great Imitator," Clinics in Dermatology, vol. 38, no. 2, pp. 140–151, 2020.

. C. V. David and N. Craft, "Cutaneous and Mucocutaneous Leishmaniasis," Dermatologic Therapy, vol. 22, no. 6, pp. 491–502, 2009.

. M. Z. Handler, P. A. Patel, R. Kapila, Y. Al-Qubati, and R. A. Schwartz, "Cutaneous and Mucocutaneous Leishmaniasis: Differential Diagnosis, Diagnosis, Histopathology, and Management," Journal of the American Academy of Dermatology, vol. 73, no. 6, pp. 911–926, 2015.

. R. Reithinger, J. C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, and S. Brooker, "Cutaneous Leishmaniasis," The Lancet Infectious Diseases, vol. 7, no. 9, pp. 581–596, 2007.

. A. A. Hussein, H. T. Al-Marsome, and H. N. Al-Musawi, "Role of IL-17 and IL-27 in Cutaneous Leishmaniasis," International Journal, vol. 3, no. 6, pp. 267–270, 2015.

. M. Ghazanfari, B. Shahriari, V. Rahnama, M. Khazaei, S. Naderi, and M. H. Motazedian, "The Level of Interleukin-17, 23, and Gamma Interferon in Cutaneous Leishmaniasis Patients Before and After Intra-Lesion Treatment," Journal of Parasitic Diseases, vol. 46, no. 2, pp. 476–482, 2022.

. A. M. Miller, "Role of IL-33 in Inflammation and Disease," Journal of Inflammation, vol. 8, pp. 1–12, 2011.

. N. Abud Al Aziz, M. A. Abudlrahman, and A. S. Mohammed, "The Relationship Between the Level of Interleukins and Some Trace Elements in the Incidence of Cutaneous Leishmaniasis," Samarra Journal of Pure and Applied Science, vol. 4, no. 4, 2022.

. I. K. Al-Aubaidi, "Serum Cytokine Production in Patients with Cutaneous Leishmaniasis Before and After Treatment," Iraqi Journal of Medical Sciences, vol. 9, no. 1, 2011.